3279 studies found for:    novartis
Show Display Options
Rank Status Study
1 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults
Conditions: Meningococcal Meningitis;   Meningococcal Infections
Interventions: Biological: Meningococcal ACWY Polysaccharide Vaccine;   Biological: MenACWY CRM (19 to 55 years);   Biological: Meningococcal ACWY Conjugate Vaccine;   Biological: Novartis MenACWY Vaccine (56 to 65 Years)
2 Recruiting Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Condition: Neoplasms
Interventions: Drug: Everolimus;   Drug: Sandostatin LAR Depot
3 Completed Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules
Condition: Meningococcal Disease
Intervention: Biological: Serogroup B meningococcal Vaccine
4 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
Conditions: Meningococcal Meningitis;   Human Papillomavirus Infection;   Pertussis;   Tetanus
Interventions: Biological: Novartis Meningococcal ACWY Conjugate Vaccine;   Biological: Tdap Vaccine
5 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
Conditions: Meningococcal Infections;   Meningococcal Meningitis
Interventions: Biological: MenACWY CRM;   Biological: Meningococcal ACWY Conjugate vaccine
6 Completed
Has Results
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
Condition: Meningococcal Infections
Interventions: Biological: MenACWY-CRM;   Biological: Licensed meningococcal ACWY vaccine
7 Completed B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: MenACWY-CRM;   Biological: DTaP-Hib_IPV;   Biological: PCV;   Biological: MMR;   Biological: Hib
8 Recruiting Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Condition: GIST and CML
Intervention: Drug: AMN107
9 Recruiting Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Conditions: Cushing's Disease,;   Acromegaly,;   Neuroendocrine Tumors,;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors,;   Dumping Syndrome,;   Prostate Cancer,;   Melanoma Negative for bRAF,;   Melanoma Negative for nRAS
Intervention: Drug: Pasireotide
10 Completed
Has Results
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: MenC-CRM LIQ;   Biological: MenC-CRM ROS;   Biological: MenC-CRM EMV
11 Active, not recruiting Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: nilotinib
12 Completed Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg
Condition: Healthy
Interventions: Drug: CJ Amlodipine/Valsartan 10/160mg;   Drug: Novartis Exforge 10/160mg
13 Recruiting Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condition: GIST and CML
Intervention: Drug: STI571
14 Recruiting Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.
Condition: Neoplasms
Intervention: Drug: Everolimus
15 Recruiting Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condition: Hematologic Neoplasms
Intervention: Drug: Panobinostat
16 Completed
Has Results
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults
Condition: Meningococcal Disease
Interventions: Biological: Men ACWY CRM;   Biological: 4CMenB
17 Completed Phase Ⅰ Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet
Condition: Healthy
Intervention: Drug: CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg
18 Not yet recruiting An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
Condition: Solid Tumors
Intervention: Drug: dovitinib
19 Not yet recruiting Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine
Conditions: Influenza, Human;   Flu, Human;   Flu, Avian;   Influenza;   Influenza A Virus, H5N1 Subtype
Interventions: Biological: Novartis Investigational H5N1 vaccine;   Biological: Novartis Seasonal Influenza Vaccine
20 Not yet recruiting Safety and Immunogenicity of Novartis Meningococcal Group B Vaccine When Administered Concomitantly With Novartis MenACWY Conjugate Vaccine to Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: rMenB+OMV and MenACWY;   Biological: rMenB+OMV;   Biological: MenACWY

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years